Mumbai-based FDC Limited has received an approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), ciprofloxacin ophthalmic solution.
Ciprofloxacin ophthalmic solution is a broad spectrum antibiotic used for occular surface infections.
The company had recently received approval for timolol maleate ophthalmic solution. Another ANDA ofloxacin ophthalmic solution is in the final stages of approval, a company release stated.